Currently, accepted clinical strategies for PCa diagnosis include a combination of the prostate-specific antigen (PSA) test, digital rectal exam, trans-rectal ultrasound (TRUS), and pelvic magnetic resonance imaging (MRI). The gene discussed is KLK3; the disease is posterior cortical atrophy.